雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Therapy for Charcot-Marie-Tooth Disease: From the Standpoint of Neurologists Masanori Nakagawa 1,2 1North Medical Center, Kyoto Prefectural University of Medicine 2Graduate School of Medical Science, Kyoto Prefectural University of Medicine Keyword: PMP22 , シグナル伝達 , 遺伝子治療 , iPS細胞 , サロゲートマーカー , PMP22 , signal pathway , gene therapy , iPS cells , surrogate markers pp.43-50
Published Date 2016/1/1
DOI https://doi.org/10.11477/mf.1416200344
  • Abstract
  • Look Inside
  • Reference

Abstract

To date, there is no approved pharmacologic treatment for any form of Charcot-Marie-Tooth disease (CMT). However, some clinical or preclinical trials for CMT1A have been undertaken, for example Neurotrophin-3, PXT3003, and neuregulin-1. Gene therapy for CMT1X, CMT2F and Giant axonal neuropathy using animal model or culture cells have been reported with some interesting results. Stem cell research for example iPS cells derived from patients with CMT2A or CMT2E, is being conducted to clarify the mechanism of CMT and find therapeutic clues. The development of new surrogate markers for clinical trials is also needed. Additionally, steps should be taken to improve the quality of life of patients with CMT, including pain control and life style enhancement.


Copyright © 2016, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

もっと見る

文献を共有